
|Articles|February 15, 2004
New drug application sought for combination IOP medication
Alcon is asking the FDA to approve a new drug application for its travoprost 0.004% plus timolol 0.5% fixed combination (TTFC) for the reduction of IOP in the treatment of glaucoma.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Neurotrophic keratitis outcomes improve with early, stage-based care
3
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5












































.png)


